BridgeBio Q3 2026 Earnings Call - BRIDGEBIO PHARMA INC

Explicit Guidance:

• 2026 Financials: Anticipate an average operating loss of approximately $92 million per quarter for the remainder of 2026.
• 2027 Financials: Expect modest steady growth in operating expenses (opex) with an improving operating line throughout 2027.
• 2028 Financials: Target reaching a break-even point in 2027, leading to standalone profitability for all four brands (Atruby, BBP418, Infogratinib, Incaloret) in 2028.
• Cash Position: As of September 30, 2026, cash, cash equivalents, and marketable securities stood at $1.5 billion, sufficient to fund operations and three upcoming launches without external financing.
• Buybacks: Continued use of the share buyback program to capture intrinsic value, with $75 million in license revenue from a one-time milestone already recorded.

Business-Segment Outlook:

• Atrubi (ATTR Cardiomyopathy):
  • Projected to track to meet or beat the $4 billion peak year sales assumption.
  • Annualizing to over $1 billion in the U.S. and significantly more globally.
  • U.S. net product revenue grew 14% QoQ ($253.2M) and 134% YoY, driven primarily by first-line new patient starts.
  • Expansion: Focus on reaching the 60% of prescribers who have not yet tried Atrubi (lower volume, non-cardiology specialists).
  • Europe: Atrubi is the leading brand; partner (Bayer) launch of Biantra in Europe is successful.
• BBP418 (LGMD2I):
  • Targeting the first approval for any limb girdle muscular dystrophy in the U.S.
  • Launch readiness: Field teams hired; 70% of MDA Care Centers contacted, targeting 90% by PDUFA.
  • Identified 500+ unique U.S. patients; EU patient population estimated at >4,000 due to founder mutation.
  • EU Timeline: MAA submission to EMA planned for H1 2028, based on 36-month final analysis with top-line data expected late 2027/early 2028.
• Infogratinib (Achondroplasia):
  • Priority review NDA accepted; PDUFA date set for February 4, 2027.
  • Launch of the only oral product for achondroplasia expected within 12 months of the latest injectable entry.
  • EU: MAA submitted; potential approval expected in H2 2027.
  • Pediatric Expansion: Phase 2/3 study (Propel 3) expanding to higher doses for hypochondroplasia to determine optimal dosing; no timeline change anticipated.
• Incaloret (ADH-1 & Chronic Hypoparathyroidism):
  • PDUFA date set for May 8, 2027; potential EU approval in H2 2027.
  • Chronic Hypoparathyroidism (RECLAIM-HP): Phase 3 trial dosed first patient; targeting ~160 patients with primary endpoint of dual calcium normalization at Week 24.
  • Top-line: Anticipated in the next 15 months.
  • Market Opportunity: Estimated 200,000 prevalent patients in U.S./EU for chronic hypoparathyroidism vs. ~25,000 for ADH-1.
  • Target Cohorts: Patients with persistent hypercalciuria (50%), osteopenic/osteoporotic individuals (risk of fracture with PTH analogs), and needle-averse patients (40%).

Market and Competitive Outlook:

• ATTR Market: Atrubi solidly in second place for new patient starts; overwhelmingly leading in the critical first-line setting. Real-world evidence (Komodo, Epic Cosmos) shows Atrubi reduces risk of clinical worsening (34%) and heart failure hospitalization (27%) vs. Tafamidis (Tefamidis).
• Competitive Landscape:
  • Combination Therapy: Market closed off for combination therapy with silencers (CardioTransform data); "stabilizer first" is the standard.
  • Payer Dynamics: No new restrictions on Atrubi from United in 2026; appeal approval rates >90%. Competitor (Vindamax) had restrictions mid-2025 but Atrubi continued growth.
  • Regulatory Challenges: Infogratinib facing a Citizen Petition from a competitor regarding CNS safety; management expects no impact on review timeline or label and views the petition as a competitive tactic.
• Pricing/Reimbursement: A "leveling" reimbursement environment in the U.S. (referencing IRA/Part D changes) expected to benefit Atrubi. Proposed ASP changes for Part B could be positive but pending final legislation.
• Diagnosis: Focus on addressing undiagnosed patient pools (e.g., launching "TypeHype" campaign for LGMD, education efforts for ATTR-CM).

Macro / Industry Outlook:

• Regulatory: FDA prioritizing "breakthrough" and "fast-track" therapies; BBP418, Infogratinib, and Incaloret all under priority review.
• Europe: Regulatory frameworks tighter than U.S., requiring longer data maturity (36 months) for EMA submission, as seen with BBP418.
• Clinical Trial Trends: Shift toward single-agent stabilization as the end-state therapy for ATTR-CM; focus on long-term functional outcomes (e.g., renal protection, cardiac structure reversal).

Strategic Initiatives:

• Launch Cadence: Executing three major launches in the next seven months (BBP418, Infogratinib, Incaloret).
• Pipeline Expansion:
  • BBP717: Nominated as next-gen monoclonal antibody depleter for ATTR; IND planned for 2027.
  • Hypoparathyroidism: Advancing Incaloret into chronic hypoparathyroidism (RECLAIM-HP) to double the addressable market beyond ADH-1.
• Commercial Innovation: Leveraging Silicon Valley roots to integrate AI and genomic sequencing (costing ~$250) to identify patients and educate physicians; modernizing commercial field force to target "long tail" prescribers.
• Capital Allocation: Prioritizing operations, then pipeline growth (via M&A or internal R&D like BBP717), followed by share buybacks.

Risks and Headwinds to Outlook:

• Regulatory/Timeline: Dependency on successful PDUFA decisions (BBP418 in Nov, Infogratinib in Feb, Incaloret in May); delays in EU submissions for BBP418 (H1 2028) due to data requirements.
• Commercial Execution: Risk of slower penetration in the "long tail" of prescribers; competition for patient diagnosis and identification in rare diseases.
• Litigation/Perception: Competitor Citizen Petition regarding Infogratinib safety (FGFR1/2 inhibition) could create perception challenges, though clinical data supports safety.
• Financial Volatility: Operating line expected to remain volatile in 2026 due to launch ramp-up costs, with breakeven targeted for 2027/2028.
• Payer Policy: Uncertainty regarding final legislative outcomes on ASP changes affecting Part B drugs.

Management Tone on the Future:

• Confidence: High confidence in meeting/peaking $4B Atrubi sales; confidence in the "stabilizer first" market narrative supported by real-world evidence.
• Execution Focus: Emphasis on "focus execution" against three launches rather than M&A at this stage; belief that operational leverage from Atrubi will fund growth.
• Differentiation: Repeated emphasis on "transformative" outcomes (e.g., BBP418 restoring biology to unaffected levels, Atrubi reversing cardiac structure) to drive market share.
• Strategic Patience: Willing to wait for full data maturity (36-months) in Europe rather than seeking accelerated approval pathways that might compromise long-term positioning.

Miscellaneous:

• R&D Update: Dosed first patient in Phase 3 chronic hypoparathyroidism trial (RECLAIM-HP).
• Data Readouts: Full CardioTransform results presented at ESC confirmed no benefit for combination therapy; ATTRIBUTES-CM data showed 54% improvement in LV systolic function.
• Financial Specifics: $75M one-time sales milestone received from Bayer for Biantra European sales.
• Patient Identification: 600+ genetically confirmed ADH-1 patients identified (up from 500), growing pipeline for Incaloret.